Sommaire

• • ·Table of Contents

    Page :A1

    
• • ·Editorial Board

    Page :A5

    
• • ·Information for Readers

    Page :A6

    

• Editorials

  • ·Risky business: Personalizing the approach to percutaneous coronary intervention

    Page :185-187

    Michael B. Rothberg, Kathryn A. Martinez

    
  • ·Predicting in-hospital worsening heart failure at time of admission, but do we really need another heart failure risk model?

    Page :188-189

    Larry A. Allen, Colleen K. McIlvennan

    

• Curriculum in Cardiology

  • ·Defining nonvalvular atrial fibrillation: A quest for clarification

    Page :161-167

    Raphaël P. Martins, Vincent Galand, Edouard Colette, Nathalie Behar, Dominique Pavin, Christophe Leclercq, Jean-Claude Daubert, Philippe Mabo

    Résumé Résumé Plan Plan  

• Trial Designs

  • ·Rationale and design of a randomized cluster trial to improve guideline-adherence of secondary preventive drugs prescription after coronary artery bypass grafting in China: Measurement and Improvement Studies of Surgical Coronary Revascularization: Secondary Prevention (MISSION-1) Study

    Page :9-18

    Chenfei Rao, Junzhe Du, Xi Li, Jing Li, Heng Zhang, Yan Zhao, Shengshou Hu, Lixin Jiang, Zhe Zheng, MISSION-1 Collaborative Group

    Résumé Résumé Plan Plan  
  • ·Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial

    Page :37-44

    Cyril Camaro, Sander A.J. Damen, Marc A. Brouwer, Elvin Kedhi, Stephan W. Lee, Monica Verdoia, Lucia Barbieri, Andrea Rognoni, Arnoud W.J. van t Hof, Erik Ligtenberg, Menko-Jan de Boer, Harry Suryapranata, Giuseppe De Luca

    Résumé Résumé Plan Plan
  • ·Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials

    Page :135-144

    Paul M. Ridker, Pierre Amarenco, Robert Brunell, Robert J. Glynn, J. Wouter Jukema, John J.P. Kastelein, Wolfgang Koenig, Steven Nissen, James Revkin, Raul D. Santos, Pamela F. Schwartz, Carla Yunis, Jean-Claude Tardif, Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Investigators

    Résumé Résumé Plan Plan   

• Clinical Investigations

  • ·Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial

    Page :1-8

    Axel Åkerblom, Robert M. Clare, Yuliya Lokhnygina, Lars Wallentin, Claes Held, Frans Van de Werf, David J. Moliterno, Uptal D. Patel, Sergio Leonardi, Paul W. Armstrong, Robert A. Harrington, Harvey D. White, Philip E. Aylward, Kenneth W. Mahaffey, Pierluigi Tricoci

    Résumé Résumé Plan Plan  
  • ·Impact of baseline mitral regurgitation on short- and long-term outcomes following transcatheter aortic valve replacement

    Page :19-27

    Sarkis Kiramijyan, Marco A. Magalhaes, Edward Koifman, Romain Didier, Ricardo O. Escarcega, Sa’ar Minha, Nevin C. Baker, Smita I. Negi, Rebecca Torguson, Jiaxiang Gai, Petros Okubagzi, Federico M. Asch, Michael A. Gaglia, Itsik Ben-Dor, Lowell F. Satler, Augusto D. Pichard, Ron Waksman

    Résumé Résumé Plan Plan  
  • ·Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease

    Page :28-36

    Hanna Fröhlich, Christoph Nelges, Tobias Täger, Vedat Schwenger, Rita Cebola, Johannes Schnorbach, Kevin M. Goode, Syed Kazmi, Hugo A. Katus, John G.F. Cleland, Andrew L. Clark, Lutz Frankenstein

    Résumé Résumé Plan Plan  
  • ·A comparison of the CHARGE–AF and the CHA₂DS₂-VASc risk scores for prediction of atrial fibrillation in the Framingham Heart Study

    Page :45-54

    Ingrid E. Christophersen, Xiaoyan Yin, Martin G. Larson, Steven A. Lubitz, Jared W. Magnani, David D. McManus, Patrick T. Ellinor, Emelia J. Benjamin

    Résumé Résumé Plan Plan   
  • ·Health-related quality of life outcomes with prasugrel among medically managed non–ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial

    Page :55-64

    Padma Kaul, E. Magnus Ohman, J. David Knight, Kevin J. Anstrom, Matthew T. Roe, William E. Boden, Judith S. Hochman, Vladimir Gašparovi?, Paul W. Armstrong, Patrick McCollam, Walid Fakhouri, Patricia Cowper, Linda Davidson-Ray, Nancy Clapp-Channing, Harvey D. White, Keith A.A. Fox, Dorairaj Prabhakaran, Daniel B. Mark, TRILOGY ACS Investigators

    Résumé Résumé Plan Plan  
  • ·The association of left ventricular ejection fraction with clinical outcomes after myocardial infarction: Findings from the Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry–Get With the Guidelines (GWTG) Medicare-linked database

    Page :65-73

    Nadia R. Sutton, Shuang Li, Laine Thomas, Tracy Y. Wang, James A. de Lemos, Jonathan R. Enriquez, Rashmee U. Shah, Gregg C. Fonarow

    Résumé Résumé Plan Plan   
  • ·Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial

    Page :74-84

    Sreekanth Vemulapalli, Anne S. Hellkamp, W. Schuyler Jones, Jonathan P. Piccini, Kenneth W. Mahaffey, Richard C. Becker, Graeme J. Hankey, Scott D. Berkowitz, Christopher C. Nessel, Günter Breithardt, Daniel E. Singer, Keith A.A. Fox, Manesh R. Patel

    Résumé Résumé Plan Plan  
  • ·Effects of interactive patient smartphone support app on drug adherence and lifestyle changes in myocardial infarction patients: A randomized study

    Page :85-94

    Nina Johnston, Johan Bodegard, Susanna Jerström, Johanna Åkesson, Hilja Brorsson, Joakim Alfredsson, Per A. Albertsson, Jan-Erik Karlsson, Christoph Varenhorst

    Résumé Résumé Plan Plan   
  • ·Association of hospital myocardial infarction volume with adherence to American College of Cardiology/American Heart Association performance measures: Insights from the National Cardiovascular Data Registry

    Page :95-101

    Robert W. Harrison, DaJuanicia Simon, Amy L. Miller, James A. de Lemos, Eric D. Peterson, Tracy Y. Wang

    Résumé Résumé Plan Plan
  • ·Effect of ColchiciNe on the InciDence of Atrial Fibrillation in Open Heart Surgery Patients: END-AF Trial

    Page :102-107

    Ramzi A. Tabbalat, Nidal M. Hamad, Imad A. Alhaddad, Ayman Hammoudeh, Bassam F. Akasheh, Yousef Khader

    Résumé Résumé Plan Plan  
  • ·Reactive hyperemia is associated with adverse clinical outcomes in heart failure

    Page :108-114

    Nicola J. Paine, Alan L. Hinderliter, James A. Blumenthal, Kirkwood F. Adams, Carla A. Sueta, Patricia P. Chang, Christopher M. O’Connor, Andrew Sherwood

    Résumé Résumé Plan Plan  
  • ·Time course, predictors, and prognostic implications of significant mitral regurgitation after ST-segment elevation myocardial infarction

    Page :115-125

    Elena Abate, Georgette E. Hoogslag, Ibtihal Al Amri, Philippe Debonnaire, Ron Wolterbeek, Jeroen J. Bax, Victoria Delgado, Nina Ajmone Marsan

    Résumé Résumé Plan Plan   
  • ·Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF)

    Page :126-134

    Gregory Y.H. Lip, Christoph Hammerstingl, Francisco Marin, Riccardo Cappato, Isabelle Ling Meng, Bodo Kirsch, Martin van Eickels, Ariel Cohen, X-TRA study and CLOT-AF registry investigators i

    Résumé Résumé Plan Plan   
  • ·Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study

    Page :145-150

    Martin J. O'Donnell, John W. Eikelboom, Salim Yusuf, Hans-Christoph Diener, Robert G. Hart, Eric E. Smith, David J. Gladstone, Mukul Sharma, Rafael Dias, Greg Flaker, Alvaro Avezum, Jun Zhu, Gayle Lewis, Stuart Connolly

    Résumé Résumé Plan Plan
  • ·Clinical and echocardiographic characteristics and outcomes in congestive heart failure at the Hospital of The State University of Haiti

    Page :151-160

    Rodolphe Malebranche, Christian Tabou Moyo, Paul-Henry Morisset, Nernst-Atwood Raphael, James Robert Wilentz

    Résumé Résumé Plan Plan  
  • ·Very early administration of glucose-insulin-potassium by emergency medical service for acute coronary syndromes: Biological mechanisms for benefit in the IMMEDIATE Trial

    Page :168-175

    Harry P. Selker, William S. Harris, Charles E. Rackley, Julian B. Marsh, Robin Ruthazer, Joni R. Beshansky, Eric J. Rashba, Inga Peter, Lionel H. Opie

    Résumé Résumé Plan Plan  
  • ·Effect of age on efficacy and safety of vorapaxar in patients with non–ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial

    Page :176-184

    Luciana V. Armaganijan, Karen P. Alexander, Zhen Huang, Pierluigi Tricoci, Claes Held, Frans Van de Werf, Paul W. Armstrong, Philip E. Aylward, Harvey D. White, David J. Moliterno, Lars Wallentin, Edmond Chen, Robert A. Harrington, John Strony, Kenneth W. Mahaffey, Renato D. Lopes

    Résumé Résumé Plan Plan  
  • ·Understanding physician-level barriers to the use of individualized risk estimates in percutaneous coronary intervention

    Page :190-197

    Carole Decker, Linda Garavalia, Brian Garavalia, Elizabeth Gialde, Robert W. Yeh, John Spertus, Adnan K. Chhatriwalla

    Résumé Résumé Plan Plan
  • ·Development and validation of a risk model for in-hospital worsening heart failure from the Acute Decompensated Heart Failure National Registry (ADHERE)

    Page :198-205

    Adam D. DeVore, Melissa A. Greiner, Puza P. Sharma, Laura G. Qualls, Phillip J. Schulte, Lauren B. Cooper, Robert J. Mentz, Peter S. Pang, Gregg C. Fonarow, Lesley H. Curtis, Adrian F. Hernandez

    Résumé Résumé Plan Plan   

• Letter to the Editors

  • ·Asymptomatic severe aortic stenosis: Cardiopulmonary exercise testing in “The World of AVATAR”

    Page :e1

    Alberto Dominguez-Rodriguez, Pedro Abreu-Gonzalez

    
  • ·Response: Asymptomatic severe aortic stenosis: Cardiopulmonary exercise testing in “the world of AVATAR”

    Page :e3

    Marko Banovic, Bernard Iung, Jozef Bartunek, Martin Penicka, Guy van Camp, Serge Nikolic, Svetozar Putnik

    
  • ·To the Editor

    Page :e5

    Rami Mohammad, Steven Borzak

    
  • ·In response to Letter to the Editor

    Page :e7

    Maya L. Chan, Paul S. Chan